Ionis Pharmaceuticals Reports Phase III Trial Success for Olezarsen in Reducing Triglycerides and Acute Pancreatitis Risk

Ionis Pharmaceuticals announced that its investigational drug olezarsen, marketed under the name Tryngolza, achieved key outcomes in a late-stage clinical trial focused on patients with severely elevated triglyceride levels. The study demonstrated that the drug not only significantly reduced triglyceride levels but also lowered the incidence of acute pancreatitis events among participants. These findings highlight potential therapeutic benefits for individuals at high risk of complications associated with hypertriglyceridemia.

The results come from a Phase III trial evaluating olezarsen’s efficacy and safety in treating severe hypertriglyceridemia, a condition linked to cardiovascular risks and acute pancreatitis. According to Ionis, the drug met its primary endpoint by achieving substantial reductions in triglyceride levels compared to placebo. Additionally, secondary data indicated a decrease in acute pancreatitis episodes among those treated with olezarsen. Analysts at BMO Capital Markets noted that these outcomes could position Tryngolza for a strong commercial debut as a first-in-class treatment option if approved. Further regulatory steps are expected following this latest development.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 3, 2025

Author

Mark Chiang